galv transduced retrovirus packaging cell line (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
95
Structured Review
ATCC
galv transduced retrovirus packaging cell line
Galv Transduced Retrovirus Packaging Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 152 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galv+transduced+retrovirus+packaging+cell+line/Phoenix-GP/pmc10751490-51-31-37
Average 95 stars, based on 152 article reviews
Galv Transduced Retrovirus Packaging Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 152 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/galv+transduced+retrovirus+packaging+cell+line/Phoenix-GP/pmc10751490-51-31-37
Average 95 stars, based on 152 article reviews
galv transduced retrovirus packaging cell line - by Bioz Stars,
2026-10
95/100 stars
Images
Related Articles
Infection:Article Title: T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation Article Snippet: .. These cell lines were infected with a modified pLZRS-Rfa retrovirus plasmid (Addgene, USA) encoding HLA-DP α and β cDNA, followed by IRES and truncated nerve growth factor receptor (ΔNGFR) using a Modification:Article Title: T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation Article Snippet: .. These cell lines were infected with a modified pLZRS-Rfa retrovirus plasmid (Addgene, USA) encoding HLA-DP α and β cDNA, followed by IRES and truncated nerve growth factor receptor (ΔNGFR) using a Plasmid Preparation:Article Title: T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation Article Snippet: .. These cell lines were infected with a modified pLZRS-Rfa retrovirus plasmid (Addgene, USA) encoding HLA-DP α and β cDNA, followed by IRES and truncated nerve growth factor receptor (ΔNGFR) using a Article Title: Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation. Article Snippet: Relapsed leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a significant challenge, with the re-emergence of the primary disease being the most frequent cause of death.. Human leukocyte antigen (HLA)DPB1 mismatch occurs in approximately 70% of unrelated allo-HSCT cases, and targeting mismatched HLA-DPB1 is considered reasonable for treating relapsed leukemia following allo-HSCT if performed under proper conditions.. In this study, we established several clones restricted to HLA-DPB1*02:01, -DPB1*04:02, and -DPB1*09:01 from three patients who underwent HLA-DPB1 mismatched allo-HSCT using donor-derived alloreactive T cells primed to mismatched HLA-DPB1 in the recipient’s body after transplantation. FACS:Article Title: T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation Article Snippet: .. These cell lines were infected with a modified pLZRS-Rfa retrovirus plasmid (Addgene, USA) encoding HLA-DP α and β cDNA, followed by IRES and truncated nerve growth factor receptor (ΔNGFR) using a Magnetic Cell Separation:Article Title: T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation Article Snippet: .. These cell lines were infected with a modified pLZRS-Rfa retrovirus plasmid (Addgene, USA) encoding HLA-DP α and β cDNA, followed by IRES and truncated nerve growth factor receptor (ΔNGFR) using a Transduction:Article Title: Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation. Article Snippet: Relapsed leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a significant challenge, with the re-emergence of the primary disease being the most frequent cause of death.. Human leukocyte antigen (HLA)DPB1 mismatch occurs in approximately 70% of unrelated allo-HSCT cases, and targeting mismatched HLA-DPB1 is considered reasonable for treating relapsed leukemia following allo-HSCT if performed under proper conditions.. In this study, we established several clones restricted to HLA-DPB1*02:01, -DPB1*04:02, and -DPB1*09:01 from three patients who underwent HLA-DPB1 mismatched allo-HSCT using donor-derived alloreactive T cells primed to mismatched HLA-DPB1 in the recipient’s body after transplantation. Retroviral:Article Title: Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation. Article Snippet: Relapsed leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a significant challenge, with the re-emergence of the primary disease being the most frequent cause of death.. Human leukocyte antigen (HLA)DPB1 mismatch occurs in approximately 70% of unrelated allo-HSCT cases, and targeting mismatched HLA-DPB1 is considered reasonable for treating relapsed leukemia following allo-HSCT if performed under proper conditions.. In this study, we established several clones restricted to HLA-DPB1*02:01, -DPB1*04:02, and -DPB1*09:01 from three patients who underwent HLA-DPB1 mismatched allo-HSCT using donor-derived alloreactive T cells primed to mismatched HLA-DPB1 in the recipient’s body after transplantation. |